tbuckley/cabot-search huggingface dataset:
Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605).
Authors: T. Hirashima, I. Okamoto, H. Yoshioka, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, H. Saka, K. Asami, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, T. Sawa, M. Miyazaki, K. Tamura, T. Kurata, M. Fukuoka, K. Nakagawa
Journal: Journal of Clinical Oncology (2011)

7552 Background: In 2010, the results of the LETS study demonstrated noninferiority for overall survival (OS) less than a predefined stopping boundary at the preplanned interim analysis (protocol-specified noninferiority margin, 1.33) (JCO 2010 28:5240). At the start of this study, we determined that a 2-year follow up would be required. Here, we report the updated results of OS. Methods: In the LETS study, chemotherapy-naïve patients with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC), Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1, and adequate organ functions were randomly assigned to receive either carboplatin AUC (5 mg/ml/min) on day 1 plus oral S-1 (80 mg/m2/day; 40 mg/m2 b.i.d.) on days 1–14 or carboplatin AUC (6 mg/ ml/min) plus paclitaxel (200 mg/m2) on day 1 every 21 days. OS was evaluated as the primary endpoint (ITT; n = 564) in the carboplatin/S-1 arm (n = 282) and carboplatin/paclitaxel arm (n = 282). This analysis used a Cox proportional hazards model adjusted for covariates such as stage (IIIB vs. IV), gender (male vs. female), and histology (adeno vs. non-adeno). In this study, we expected 442 events. Results: In the overall population, median OS (446 deaths; 79%) was 15.2 months (95% CI, 12.3–17.8) in the carboplatin/S-1 arm and 13.1 months (95% CI, 11.7–14.9) in the carboplatin/paclitaxel arm. The adjusted 95% CI of the hazard ratio for OS of 0.956 was 0.793–1.151 in the ITT population. The safety profile was consistent with a previously established one. In squamous cell carcinoma (Sq), median OS was 14.0 months (95% CI, 11.4–16.7) in the carboplatin/S-1 arm and 10.55 months (95% CI, 8.7–12.6) in the carboplatin/paclitaxel arm. The adjusted 95% CI of the hazard ratio for OS of 0.713 was 0.476–1.068. Conclusions: This updated data shows reproducible results. Therefore, carboplatin plus S-1 is a therapeutic option for first-line treatment of advanced NSCLC. Future prospective studies should evaluate the efficacy of carboplatin plus S-1for treating Sq.
Immunoglobulins Intrinsic to Colorectal Carcinoma: An Unfavorable Prognostic Association With IgM&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: S L Jones, E Pihl, A M Cuthbertson, E S Hughes, W R Johnson, A J Rollo
Journal: JNCI Journal of the National Cancer Institute (1983)

Immunoglobulin (Ig) eluates prepared from cell membrane fractions of 50 colorectal carcinomas were found to contain significantly (P less than .001) less IgA and IgM and marginally less IgG than normal colon mucosa. IgA and IgG were present in all tumors, but IgM was present in only 20 of 50 tumors (40%). Small (less than or equal to the median vol) tumors contained significantly (P less than .05) more IgA and IgG per gram tissue than did large tumors. Tumors with a large (greater than the median) proportion of stroma contained more IgG than did those with less stroma. No associations were found between Ig and amount of viable-appearing tumor tissue, necrosis, mucin production, and staging. Patients whose tumors contained measurable amounts of IgM had a significantly (P = .012) shorter survival than did patients without intrinsic IgM (12 and 27 mo at the 75th percentile, respectively). The difference could not be explained by conventional staging.
The psychodynamics and developmental psychology of the borderline patient: a review of the literature
Authors: E R Shapiro
Journal: American Journal of Psychiatry (1978)

The author reviews the psychodynamics and developmental psychology of the borderline patient as described in the literature on intensive therapy, early mother-child interaction, and family interaction. Focusing on the borderline patient's characteristic difficulties in intimate relationships, he describes the patient's use of splitting and projective identification as seen in the characteristic transference-countertransference interaction in intensive therapy. These primitive defensive mechanisms, which are also utilized by family members, appear to contribute to a failure of empathic responses both during the child's early development and in the family interactions during his adolescence. The author concludes that conceptual attempts to relate adult and child phenomena, although highly speculative, create new and useful perspectives for the treatment of the borderline patient.
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Authors: Christina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, Merete Paludan, Eva Rønnengart, Ulrich Halekoh, Felix Hilpert, Petra Feyer, Gunnar Kristensen, Olfred Hansen, Dorothy Keefe, Jørn Herrstedt
Journal: The Lancet Oncology (2016)
Gastric Polyps – Frequency,Types, Endoscopic Features and Associations
Authors: A Maguire, S Sebastian, R McLoughlin, A Qasim, P Crotty, H O'Connor, M Buckley, C O'Morain
Journal: Endoscopy (2004)

Gastric polyps are not uncommonly identified at endoscopy. Studies differ on the type, frequency and associations of gastric polyps.
Advanced testicular cancer: treatment choices in the "land of plenty".
Authors: M B Garnick
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.3.294 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2579211 Advanced testicular cancer: treatment choices in the "land of plenty". M B GarnickxM B GarnickSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.3.294 First Page PDF © 1985 by American Society of Clinical Oncology
Detection of metastases in breast cancer: Is whole body PET/MR better than PET/CT?
Authors: Eleonora Teplinsky, Akshat Pujara, Francisco J. Esteva, Linda Moy, Amy Melsaether, Komal L. Jhaveri
Journal: Journal of Clinical Oncology (2014)

15 Background: Whole body PET/CT is commonly utilized in breast cancer (BC) patients (pts). Limitations include assessment of treatment response in bone metastases (mets), high physiologic uptake in brain and liver, and cumulative radiation exposure. The site of mets can have prognostic and therapeutic implications. PET/MR, an exciting new hybrid technology, delivers less radiation than PET/CT. Our aim was to compare the differences in metastatic lesion detection using PET/CT &amp; PET/MR in all BC subtypes. Methods: After a single 18-FDG injection, pts had whole body PET/CT for staging and assessment of treatment response. They were transported to another NYU facility &amp; then underwent whole body PET/MR. PET/MR &amp; PET/CT images were each read by a radiologist blinded to prior exams or reports. Number of mets (up to 6) per organ was recorded. 2 experienced radiologists unblinded to imaging and pathology reports served as the “reference standard”. Results: Forty-eight BC pts underwent PET/CT &amp; PET/MR (28 in metastatic setting, 5 for staging &amp; 15 to rule out recurrence). Median age: 55; range 32-79 with 31 ER+/HER2-, 8 ER+/HER2+, 2 ER-/HER2+, 6 ER-/HER2+, 1 unknown. 20 pts had no distant mets on scan. In the remaining 28 pts, the reference standard detected 9 liver, 18 bone, 7 lung/pleura, 5 brain &amp; 10 lymph node (LN) metastases; some patients had ≥1 metastatic site. PET/CT had more false positives (FP) and false negatives (FN) in the detection of mets (Table). PET/MR had 1 FP in the liver. PET/MR accurately detected 2 bone (ER+/HER2-), 3 liver (ER+/HER2-), 2 LN (1 ER+/HER2+; 1 ER+/HER2-) and 5 brain lesions (1 ER+/HER2-; 3 ER-/HER2+; 1 ER+/HER2+) in 10 unique pts that were not identified on PET/CT. 1 liver (ER+/HER2-) and 2 brain mets (ER-/HER2+) identified on PET/MR were previously unknown. Conclusions: Our preliminary data suggest that PET/MR outperformed PET/CT in detecting mets in the liver, brain, LN &amp; possibly bone. Prospective studies of PET/MR are warranted to determine whether early detection of mets, including occult brain mets in HER2+ pts, impacts survival.[Table: see text]
Court-mandated community outpatient treatment for persons found not guilty by reason of insanity: a five-year follow-up
Authors: H R Lamb, L E Weinberger, B H Gross
Journal: American Journal of Psychiatry (1988)

The authors conducted a 5-year follow-up study of 79 persons found not guilty by reason of insanity who were referred to and accepted for court-mandated community outpatient treatment. This was a severely mentally ill and violent group with extensive experience in both the criminal justice and mental health systems. This program was not without risks despite a readiness to revoke the patients' conditional release status when indicated; during the 5-year follow-up period, 25 (32%) were rearrested (18 [72%] for crimes of violence), 37 (47%) were hospitalized, and 38 (48%) had their conditional releases revoked. The authors believe that members of this population need social controls and long-term treatment when they are in the community.
Abstract MP070: Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes: Two Independent Studies
Authors: Qibin Qi, Frank B Hu, Lu Qi
Journal: Circulation (2012)

Background Hypertension has been associated with an increased risk of cardiovascular disease (CVD).We examined the effect of the genetic predisposition to high blood pressure and its potential interactions with diet and lifestyle factors on risk of cardiovascular complications among diabetic patients. Methods The present study included 1005 men and 1299 women with type 2 diabetes from the Health Professionals Follow-up Study and Nurses’ Health Study: 732 (380 men and 352 women) CVD cases (coronary heart disease [CHD] or stroke) and 1572 non-CVD controls. Genetic predisposition to high blood pressure was estimated by a genetic risk score on basis of 29 blood pressure-predisposing variants identified by a recent GWAS meta-analysis in ∼200,000 Europeans. Results The genetic risk score was associated with prevalent hypertension in both men and women, with a combined OR of 1.07 (95% CI 1.04-1.09) for each additional risk allele. Restricted cubic spline regression analysis indicated a linear relationship between the genetic risk score and increased CVD risk in both men ( P =0.002) and women. ( P =0.028) ( Figure ). The results from the 2 cohorts were combined since the genetic risk score showed consistent associations in men and women. After adjustment for age, BMI, and diet and lifestyle risk factors, each additional risk allele in the genetic risk score was associated with a 5% increased risk of developing CVD (OR 1.05 [95% CI 1.02-1.09]). The OR was 1.49 (1.08-2.07) for CVD when comparing the extreme quartiles of the genetic risk score ( P for trend =0.007). We did not observe significant interactions of the genetic risk score with Dietary Approach to Stop Hypertension diet score, and other lifestyle risk factors such as BMI, physical activity, alcohol intake, use of nonnarcotic analgesics and supplemental folic acid intake. Conclusions Genetic predisposition to high blood pressure is associated with an increased risk of cardiovascular complications in diabetic patients, independent of diet and lifestyle risk factors for hypertension.
Effect of Antiviral Antibody on Virus-Cell Interactions in Turkey Rous Sarcoma Cells&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Victor V. Bergs, Vincent Groupé
Journal: JNCI Journal of the National Cancer Institute (1962)

The release of Rous sarcoma virus from turkey-embryo cells infected in vitro started after an eclipse period of 29 to 34 hours and increased gradually until a plateau was reached between the 5th and 7th day. The development of cell-associated antigen, as followed by fluorescent antibody, paralleled the rise of infectious virus in the supernatant. Fluorescence was first seen at about 30 hours post infection in the form of fine cytoplasmic granules and increased gradually, involving more cells and becoming more diffuse. The bulk of antigen was located at the cell surface, lining the cell membranes. The location of antigen was the same in turkey tumor cells grown in vitro. It was shown to be accessible to antiviral antibody that removed most of the cell-associated virus. In addition, antibody prevented spread of newly formed virus to susceptible cells in turkey-embryo cell cultures initially infected with low doses of virus. It was further shown that cells obtained by trypsinization of tumor tissue from birds with high levels of circulating antibody contained little or no detectable virus. Attempts to “cure” tumor cells of virus by continuous exposure to antibody for several months in vitro were unsuccessful. It is suggested that circulating antiviral antibody is an important cause in failure to recover virus, not only from tumor-tissue extracts but also from trypsinized and washed tumor cells.
Abstract 19392: Endothelial Knockout of Polycystin 1 (PC1) Alters Mitochondrial Functions and Bioenergetics
Authors: Yuh Fen Pung, Ravi K Adapala, Jamie R Burke, Werner J Geldenhuys, William M Chilian, Charles K Thodeti, Thomas J Jones
Journal: Circulation (2012)

Polycystin 1 (PC1) is a mechanosensitive component of shear stress sensing in endothelial cells. Shear stress is a critical determinant of endothelial proliferation, migration and differentiation, which are energy dependent processes. Since, mutations in PC1 impair shear-induced endothelial functions, we hypothesized PC1 may mediate its effects through mitochondrial-dependent energy production. In the present study, we measured mitochondrial function using the Seahorse XF24-3 flux analyzer in wild type and PC1 null endothelial cells. We found that the maximal oxygen consumption rate (OCR) and extracellular acidification rate (glycolysis) (ECAR) were 2-fold lower in PC1 null cells compared to Wt (p&lt;0.05) in response to the mitochondrial uncoupler, FCCP (0.5 µmol/L). PC1 null cells also exhibited a 10-fold reduction in bioenergetic reserve capacity (p&lt;0.05), indicating a severe mitochondrial dysfunction. Further, we found these cells show a 3.5-fold decrease in peroxisome proliferator-activated receptors gamma (PPAR gamma) coactivator-1 alpha (PGC-1 alpha) and a 4-fold decrease in the mitochondrial uncoupling protein 2 (UCP2) expression. Importantly, the mutant cells showed a 2-fold increase in the mitochondrial membrane potential as measured by a selective mitochondrial potential indicator, JC-1. Finally, we found that PC1 null cells showed an increased production of ROS as assessed by DHE and Mitosox staining. Importantly, there were no changes in mitochondrial abundance between PC1 and WT cells. Taken together, these results indicate the absence of PC1 impairs mitochondrial function and may contribute to the endothelial dysfunction observed in polycystic kidney disease (PKD).
Author’s reply: Is there a need for special treatment of refugees at hospital admission?
Authors: Volkhard A.J. Kempf, Ursel Heudorf
Journal: Eurosurveillance (2016)

Preview this article: Author’s reply: Is there a need for special treatment of refugees at hospital admission?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/7/eurosurv-21-30138-5-1.gif
Loss of immunoproteasome driven by EMT is associated with immune evasion and poor prognosis in non-small cell lung cancer
Authors: Satyendra C. Tripathi, Haley L. Peters, Ayumu Taguchi, Hiroyuki Katayama, Hong Wang, Amin Momin, Mohit K. Jolly, Muge Celiktas, Jaime Rodriguez, Hui Liu, Carmen Behrens, Ignacio I. Wistuba, Herbert Levine, Jeffrey J. Molldrem, Samir M. Hanash, Edwin J. Ostrin
Journal: Journal of Thoracic Oncology (2016)
Bortezomib in refractory ANCA-associated vasculitis: a new option?
Authors: Pavel Novikov, Sergey Moiseev, Nikolay Bulanov, Elena Shchegoleva
Journal: Annals of the Rheumatic Diseases (2015)

Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma. Proteasome inhibition depletes short-lived and long-lived plasma cells and is a promising therapeutic approach to treat refractory antibody-mediated autoimmune diseases. In a small uncontrolled study from Charite (Berlin), recently published in the Annals of the Rheumatic Diseases , 12 patients with systemic lupus erythematosis (SLE) with persistent disease activity and autoantibody production despite immunosuppression were treated with bortezomib according to the approved protocol for multiple myeloma.1 Disease activity declined significantly, though adverse events occurred in 11 of 12 patients and resulted in discontinuation of bortezomib in seven of them.

Resistance to immunosuppressive treatment, including cyclophosphamide (CYC) and …
Treatment in the air
Authors: M. Bagshaw
Journal: BMJ (1995)

its mother so modest matemal fevers may lead to fetal temperatures approaching 40°C, which could be dangerous for the baby.2In addition, maternal raised body temperature leads to fetal tachycardia which may be misinterpreted as fetal distress, leading to intervention.2Unlike normal labour rooms (usually kept at 26-28°C), birthing pools are close to body temperature and can therefore prevent the normal loss of heat that is necessary to maintain maternal isothermia.In our unit the protocol for use of the pool originally suggested keeping the water at 37-38°C.In the light of our audit, we now recommend maintaining the temperature at 36-37°C, with hourly monitoring.Prospective research is urgently needed to determine the optimum water temperature for safe use of the birthing pool.This is particularly important in the light of the surprising length of time some women spend in the pool.
A new biweekly schedule of carboplatin and gemcitabine: Phase I feasibility trial in patients with advanced non-small cell lung cancer (NSCLC)
Authors: A. Mancuso, M. R. Migliorino, O. Martelli, R. Belli, M. Di Molfetta, L. De Petris, R. Di Salvia, F. De Marinis
Journal: Journal of Clinical Oncology (2004)

7245 Background: In preclinical trials, Carboplatin (C) followed by Gemcitabine (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of C and G administered respectively on days 1,2 every 15. Methods: Eligible criteria were a stage IIIb/IV NSCLC, age ≤ 80 years, ECOG Performance Status 1 or 2, adequate marrow, renal and hepatic functions. The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three patients entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m2) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any ≥ grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific toxicity. Results: Between March and August 2003, 18 chemo naïve pts were enrolled and received 52 cycles (median cycles 3, range 1–6) at 6 dose levels: male/female =15/3, median age =70 (range:65–80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related toxicities (NCI grading scale) included neutropenia grade 2/3/4, 2%/6%/19%, anemia grade 1/2/3, 52%/11%/2%, thrombocytopenia grade 1/2/3, 15%/6%/2%. All grade neutropenia and thrombocytopenia lasted <7 days. Other non-hematologic toxicities (nausea, fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 neurotoxicity resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m2). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable patients. Conclusions: The schedule's manageable toxicity profile and activity have encouraged an ongoing phase II trial at doses of Carboplatin AUC = 4.5 and Gemcitabine 1500 mg/m2 including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.
Corrigendum to “BDNF protects pancreatic β cells (RIN5F) against cytotoxic action of alloxan, streptozotocin, doxorubicin and benzo(a)pyrene in vitro” METABOLISM CLINICAL AND EXPERIMENTAL 65 (2016) 667–684
Authors: Siresha Bathina, Nanduri Srinivas, Undurti N. Das
Journal: Metabolism (2016)
Unique Apoptotic Effects Of Panobinostat and Marizomib In Acute Myeloid Leukemia and Bortezomib-Resistant Models
Authors: Fernando F. Corrales-Medina, Daniela E. Egas Bejar, Christa Manton, Blake Johnson, Mary E Irwin, Robert Z. Orlowski, Joya Chandra
Journal: Blood (2013)
Development of Nononcogenic SA7-Adeno-virus 2 Populations That Immunize Against SA7-Transformed Cells<xref ref-type="fn" rid="FN2">2</xref>
Authors: Paul M. Kaplan, Joseph L. Melnick, Satvir S. Tevethia
Journal: JNCI Journal of the National Cancer Institute (1971)

Several SA7-adenovirus 2 (SA7-Ad2) populations were isolated from progeny obtained after simian cells were doubly infected with simian adenovirus, SA7, and human adenovirus type 2. The SA7-Ad2 isolates induced the synthesis of SA7 T antigen, replicated in simian cells, were antigenically adenovirus 2, and also contained an excess of normal Ad2 virions. The SA7-Ad2 particle which replicated in simian cells was defective as demonstrated by 1) two-hit kinetics of plaque formation in simian cells, and 2) enhanced plaque formation in simian cells in the presence of additional helper human Ad2. Therefore the SA7-Ad2 populations are composed of defective SA7 genomes in Ad2 capsids and complete Ad2. The populations containing the defective particles were nononcogenic in hamsters, while the parental SA7 from which they were derived was highly oncogenic. Although these viruses were nononcogenic, they were able to induce immunity against SA7-induced tumor cells.
Improved Gene Transfer Into Baboon Marrow Repopulating Cells Using Recombinant Human Fibronectin Fragment CH-296 in Combination With Interleukin-6, Stem Cell Factor, FLT-3 Ligand, and Megakaryocyte Growth and Development Factor
Authors: Hans-Peter Kiem, Robert G. Andrews, Julia Morris, Laura Peterson, Scott Heyward, James M. Allen, John E.J. Rasko, Jennifer Potter, A. Dusty Miller
Journal: Blood (1998)